{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:15:53Z","timestamp":1774548953537,"version":"3.50.1"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.lungcan.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T22:33:06Z","timestamp":1620167586000},"page":"48-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials"],"prefix":"10.1016","volume":"157","author":[{"given":"Navin K.","family":"Chintala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4469-3879","authenticated-orcid":false,"given":"David","family":"Restle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hue","family":"Quach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-8271","authenticated-orcid":false,"given":"Jasmeen","family":"Saini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Bellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3018","authenticated-orcid":false,"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-2425","authenticated-orcid":false,"given":"Jason","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2046","authenticated-orcid":false,"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2021.05.004_bib0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the united states: a surveillance, epidemiology, and end results (seer)-medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin. Epidemiol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2017.02.026","article-title":"Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma","volume":"12","author":"Shaikh","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"10","key":"10.1016\/j.lungcan.2021.05.004_bib0020","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.lungcan.2021.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0030","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0035","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","article-title":"Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma","volume":"60","author":"Bograd","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.lungcan.2021.05.004_bib0040","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase iii trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the european thoracic oncology platform (etop 9-15) promise-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (determine): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10272","key":"10.1016\/j.lungcan.2021.05.004_bib0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (checkmate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"6230","key":"10.1016\/j.lungcan.2021.05.004_bib0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.004_bib0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of cd19 car therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.004_bib0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.lungcan.2021.05.004_bib0070","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor t cells in refractory b-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (zuma-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.lungcan.2021.05.004_bib0080","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel car t-cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2021.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"Kte-x19 car t-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"Cd22-targeted car t cells induce remission in b-all that is naive or resistant to cd19-targeted car immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0095","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific car t cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.004_bib0100","first-page":"166","article-title":"FDA approves fourth car-t cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lungcan.2021.05.004_bib0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/bs.ircmb.2016.10.002","article-title":"Antibody-based cancer therapy: successful agents and novel approaches","volume":"331","author":"Hendriks","year":"2017","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0110","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2021.05.004_bib0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.004_bib0120","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.004_bib0125","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-20-3392","article-title":"Preclinical characterization of HPN536, a trispecific, T-cell-activating protein construct for the treatment of mesothelin-expressing solid tumors","volume":"27","author":"Molloy","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.004_bib0130","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting bites circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.lungcan.2021.05.004_bib0135","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lungcan.2021.05.004_bib0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover mhc class i in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.004_bib0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"16","key":"10.1016\/j.lungcan.2021.05.004_bib0160","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.004_bib0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2017.10.001","article-title":"Chimeric antigen receptor (car) t-cell therapy for thoracic malignancies","volume":"13","author":"Kiesgen","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0175","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.lungcan.2021.05.004_bib0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0185","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (ceacam5)-specific car t cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0195","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0200","first-page":"181","article-title":"Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium","volume":"52","author":"Chang","year":"1992","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.004_bib0205","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.004_bib0210","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0215","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-muc16 binding is a high affinity, n-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0220","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.lungcan.2021.05.004_bib0225","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.004_bib0230","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1055-9965.EPI-11-0993","article-title":"Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett\u2019s associated esophageal adenocarcinoma","volume":"21","author":"Rizk","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"261","key":"10.1016\/j.lungcan.2021.05.004_bib0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting cd4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.004_bib0240","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lungcan.2021.05.004_bib0245","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-12-615","article-title":"Re-directed t cells for the treatment of fibroblast activation protein (fap)-positive malignant pleural mesothelioma (fapme-1)","volume":"12","author":"Petrausch","year":"2012","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.lungcan.2021.05.004_bib0250","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.004_bib0255","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.lungcan.2021.05.004_bib0260","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting fap-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0265","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lungcan.2021.05.004_bib0270","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary\u2019 t4 immunotherapy\u2019 of malignant mesothelioma using pan-erbb re-targeted car t-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.004_bib0275","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.lungcan.2012.03.008","article-title":"Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma","volume":"77","author":"Al-Taei","year":"2012","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/bjc.1990.20","article-title":"Immunohistological distribution of 5t4 antigen in normal and malignant tissues","volume":"61","author":"Southall","year":"1990","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.004_bib0285","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/cancers9090115","article-title":"Chimeric antigen receptor (car) t cell therapy for malignant pleural mesothelioma (mpm)","volume":"9","author":"Klampatsa","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.lungcan.2021.05.004_bib0290","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1158\/1078-0432.CCR-12-0628","article-title":"CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma","volume":"18","author":"Rivera","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2051-1426-2-25","article-title":"Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells","volume":"2","author":"Beard","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"issue":"177","key":"10.1016\/j.lungcan.2021.05.004_bib0305","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"Cd19-targeted t cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0310","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","article-title":"Inducible activation of myd88 and cd40 in car t cells results in controllable and potent antitumor activity in preclinical solid tumor models","volume":"7","author":"Mata","year":"2017","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0315","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"Ox40 costimulation by a chimeric antigen receptor abrogates cd28 and il-2 induced il-10 secretion by redirected cd4(+) t cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.004_bib0320","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.004_bib0325","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2326-6066.CIR-15-0054","article-title":"Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.004_bib0330","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0335","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of car activation potential directs alternative t cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.lungcan.2021.05.004_bib0340","article-title":"Abstract lb-378: regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic pd-1 checkpoint blockade: translation to a phase i trial","volume":"80","author":"Kiesgen","year":"2020","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0345","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single residue in cd28-costimulated CAR-T cells limits long-term persistence and antitumor durability","volume":"130","author":"Guedan","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.lungcan.2021.05.004_bib0350","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0355","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0360","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2021.05.004_bib0365","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.004_bib0370","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0375","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing il-18 convert to t-bet(high) foxo1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.004_bib0380","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of il15 improves antiglioma activity of il13ralpha2-car T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.004_bib0385","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","article-title":"Eradication of neuroblastoma by T cells redirected with an optimized gd2-specific chimeric antigen receptor and interleukin-15","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.004_bib0390","doi-asserted-by":"crossref","first-page":"e1395997","DOI":"10.1080\/2162402X.2017.1395997","article-title":"Intra-tumoral delivery of cxcl11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"Oncoimmunology"},{"issue":"14","key":"10.1016\/j.lungcan.2021.05.004_bib0395","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.004_bib0400","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.004_bib0405","doi-asserted-by":"crossref","first-page":"e56820","DOI":"10.1371\/journal.pone.0056820","article-title":"Co-introduced functional ccr2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express wt1-specific T-cell receptor","volume":"8","author":"Asai","year":"2013","journal-title":"PLoS One"},{"issue":"328","key":"10.1016\/j.lungcan.2021.05.004_bib0410","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"Pd-l1 (b7-h1) and pd-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.lungcan.2021.05.004_bib0415","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.004_bib0420","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a pd-1-blocking scfv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0425","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0430","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"Crispr\/cas9-mediated pd-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0435","doi-asserted-by":"crossref","first-page":"e133977","DOI":"10.1172\/jci.insight.133977","article-title":"Tgf-beta inhibition via crispr promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2021.05.004_bib0440","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-pd-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"13_suppl","key":"10.1016\/j.lungcan.2021.05.004_bib0445","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract ct036: a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res."},{"issue":"5_suppl","key":"10.1016\/j.lungcan.2021.05.004_bib0450","doi-asserted-by":"crossref","first-page":"v501","DOI":"10.1093\/annonc\/mdz253.052","article-title":"A phase i clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-fap-targeted CAR T-cells","volume":"30","author":"Curioni","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.004_bib0455","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"Il-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.004_bib0460","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.004_bib0465","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","article-title":"Anti-gd2\/4-1bb chimeric antigen receptor T cell therapy for the treatment of chinese melanoma patients","volume":"11","author":"Yu","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0475","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.004_bib0480","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI87624","article-title":"Biopolymers codelivering engineered T cells and sting agonists can eliminate heterogeneous tumors","volume":"127","author":"Smith","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"26","key":"10.1016\/j.lungcan.2021.05.004_bib0485","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.004_bib0490","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0495","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0500","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0505","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of fapme, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2021.05.004_bib0510","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3014","article-title":"Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma","volume":"38","author":"Annunziata","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.05.004_bib0515","series-title":"TCR2 Therapeutics Announces Recist Responses With First TC-210 Dose Tested in Advanced Mesothelin-expressing Solid Tumors","year":"2020"},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.004_bib0520","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2021.05.004_bib0525","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3389\/fimmu.2019.02857","article-title":"Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells","volume":"10","author":"Lai","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0530","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0535","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"Nkg2d-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0540","doi-asserted-by":"crossref","first-page":"1757360","DOI":"10.1080\/2162402X.2020.1757360","article-title":"Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model","volume":"9","author":"Murty","year":"2020","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.004_bib0545","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"Cd40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.004_bib0550","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein wt1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.004_bib0555","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1158\/0008-5472.CAN-17-0469","article-title":"Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma","volume":"78","author":"Reap","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.004_bib0560","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4161\/hv.27678","article-title":"Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma","volume":"10","author":"Shimizu","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"15","key":"10.1016\/j.lungcan.2021.05.004_bib0565","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:53:34Z","timestamp":1759236814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":113,"alternative-id":["S0169500221001720"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}